Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today that Legacy
Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has
commenced production of Reme-Flu™ and expects it to be ready for
consumer purchase within the next 30 days. Reme-Flu™ is Legacy
Biotechnologies’ unique 2-part homeopathic flu remedy designed to help
treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the
top-rated website, www.nutralegacy.com.
Nutralegacy.com, a site dedicated to education regarding a multitude of
health related topics, receives an average of 190,000 unique visits
every month. To mark the introduction of Reme-Flu™, Legacy
Biotechnologies will be offering special incentives in order to make
this important homeopathic flu remedy available to as many people as
possible. It is vital to let consumers know that with Reme-Flu™, there
is now a safe and effective way to treat symptoms of the flu –
especially as seasonal weather patterns begin to change.
In addition, as Reme-Flu™ nears completion, Legacy Biotechnologies is
actively pursuing an agreement with a major marketing company to work
directly with both the sales and marketing of Reme-Flu™ in the retail
sector. Legacy anticipates that a formal marketing agreement will be
reached within the next week.
Martin Schmieg, President and CEO of Nuvilex, Inc., has stated that he
is very pleased to see the production of Reme-Flu™ begin and feels that
this remedy will be a great asset to help people of all ages overcome
symptoms of the flu. The combination of a strong internet presence
coupled with proven marketing methods will create a strong synergy in
helping to quickly build sales and brand awareness of Reme-Flu™.
AI model predicts flu vaccine strains more accurately than WHO